Factors associated with the relapse of infantile haemangiomas in children treated with oral propranolol

Br J Dermatol. 2013 Dec;169(6):1252-6. doi: 10.1111/bjd.12432.

Abstract

Background: Although propranolol has become the first-line therapy for infantile haemangiomas (IHs), no study has yet investigated factors associated with the risk of relapse in children with IH treated with propranolol after cessation of treatment.

Objectives: To compare factors associated with the risk of relapse in children with IH treated with oral propranolol.

Methods: We conducted a single-centre retrospective observational study. All files and photographs of patients with IH aged 5 months or less at the time of treatment initiation, and who were seen between 1 June 2008 and 31 December 2011 at the National Reference Center for rare skin diseases of Bordeaux, were retrospectively reviewed.

Results: In total 158 children were included, of whom 118 had not relapsed and 40 had relapsed. Fifty-two patients were boys and 106 were girls (male : female ratio 1 : 2), and 19 had a segmental IH (12%). When conducting multivariate analysis, only IHs with a deep component and those with segmental distribution were independently associated with relapse.

Conclusions: Our study shows that segmental IHs, as well as haemangiomas with a deeper component, are more at risk of relapse and should thus indicate closer follow-up after treatment interruption, and/or longer treatment.

Publication types

  • Observational Study

MeSH terms

  • Administration, Oral
  • Antineoplastic Agents / administration & dosage*
  • Child
  • Child, Preschool
  • Female
  • Head and Neck Neoplasms / drug therapy*
  • Hemangioma / drug therapy*
  • Humans
  • Infant
  • Male
  • Neoplasm Recurrence, Local / etiology*
  • Propranolol / administration & dosage*
  • Retrospective Studies
  • Skin Neoplasms / drug therapy*
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Propranolol